Euroopan unioni -
englanti -
EMA (European Medicines Agency)
lamivudine teva pharma b.v.
teva b.v. - lamivudine - hiv infections - antivirals for systemic use - lamivudine teva pharma b.v. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (hiv)-infected adults and children.
Irlanti -
englanti -
HPRA (Health Products Regulatory Authority)
esomeprazole teva pharma 20 milligram tablets gastro-resistant
teva pharma b.v. - esomeprazole - tablets gastro-resistant - 20 milligram - proton pump inhibitors
Irlanti -
englanti -
HPRA (Health Products Regulatory Authority)
esomeprazole teva pharma 40 milligram tablets gastro-resistant
teva pharma b.v. - esomeprazole - tablets gastro-resistant - 40 milligram - proton pump inhibitors
Euroopan unioni -
englanti -
EMA (European Medicines Agency)
biograstim
abz-pharma gmbh - filgrastim - neutropenia; hematopoietic stem cell transplantation; cancer - colony stimulating factors - biograstim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.biograstim is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.biograstim is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Malta -
englanti -
Medicines Authority
ramipril/hydrochlorothiazide tad 2.5 mg/12.5 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril, hydrochlorothiazide - tablet - ramipril 2.5 mg hydrochlorothiazide 12.5 mg - agents acting on the renin-angiotensin system
Malta -
englanti -
Medicines Authority
ramipril/hydrochlorothiazide tad 5 mg/25 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril, hydrochlorothiazide - tablet - ramipril 5 mg hydrochlorothiazide 25 mg - agents acting on the renin-angiotensin system
Malta -
englanti -
Medicines Authority
ramipril tad 1.25 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system
Malta -
englanti -
Medicines Authority
ramipril tad 2.5 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system
Malta -
englanti -
Medicines Authority
ramipril tad 5 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system
Malta -
englanti -
Medicines Authority
ramipril tad 10 mg tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system